Amgen
Pharma

ESMO: Amgen’s Imdelltra stages Rasonque-like moment in SCLC

When added on top of AstraZeneca’s Imfinzi, Imdelltra reduced the risk of death by 58% as a first-line maintenance therapy in extensive-stage SCLC.
Angus Liu Oct 24, 2026 10:30am
On target clinical trial success bullseye score

Bristol CMO touts more ph. 3 wins for bispecific ADC iza-bren

Oct 26, 2026 3:30am
Xia

Akeso CEO looks for more ivonescimab combos after AZ deal

Oct 25, 2026 11:30am
AstraZeneca

ESMO: AZ, Hutchmed’s Orpathys combo shows post-Tagrisso power

Oct 25, 2026 11:30am
horses racing

Merck’s sac-TMT posts major PFS benefit in PD-L1-negative NSCLC

Oct 25, 2026 5:15am
AZ

ESMO: AstraZeneca pitches own Padcev combos in bladder cancer

Oct 24, 2026 10:30am
More News

Bayer's Nubeqa eyes wider market after phase 3 win

Oct 24, 2026 8:30am

Argenx reports Q3 sales bump and a new trial requirement

Oct 23, 2026 11:42am

Gilead to pay $45M to resolve kickback allegations in Texas

Oct 23, 2026 10:57am

The Oral GLP-1 Tracker: Lilly, Novo see script dip amid holiday

Oct 23, 2026 9:51am